{
  "pathway_name": "rectal-cancer-clinical-pathways-v1-2025-508h",
  "original_file": "rectal-cancer-clinical-pathways-v1-2025-508h_extracted.json",
  "processed_at": "2025-03-29T01:07:48.292261",
  "complete_summary": {
    "response": "# COMPREHENSIVE CLINICAL PATHWAY FOR RECTAL CANCER (2025)\n\n## I. INITIAL EVALUATION AND STAGING\n\n### A. Definitions and Anatomic Considerations\n- **Rectal Definition**: Intestine below a virtual line from sacral promontory to upper edge of pubic symphysis, extending to the anus (defined on rectal MRI)\n\n### B. Initial Evaluation Framework\n1. **Mode of Diagnosis Assessment**:\n   - **Complete resection**: Follow pathway based on pathological stage\n   - **Biopsy/partial resection**: Perform staging workup\n      - **T and N staging**: Rectal protocol MRI (preferred) or Endoscopic Ultrasound (EUS)\n      - **M staging**: CT of chest, abdomen, and pelvis (if MRI pelvis not performed)\n\n2. **Veterans Affairs Presumptive Service Connection**:\n   - Eligible if served:\n     - On/after September 11, 2001 in: Afghanistan, Djibouti, Egypt, Jordan, Lebanon, Syria, Uzbekistan, or Yemen; OR\n     - On/after August 2, 1990 in: Southwest Asia theater of operations or Somalia\n\n## II. MOLECULAR TESTING FRAMEWORK\n\n### A. Somatic Testing by Stage\n1. **Stage I-III**:\n   - MMR protein expression by IHC and/or microsatellite instability by PCR\n   - If deficient (dMMR/MSI-H): Consider Lynch testing if germline testing not previously done\n   \n2. **Stage IV**:\n   - Comprehensive genomic profiling (CGP)\n   - MMR testing\n   - HER2 status by IHC (reflex to FISH if IHC 2+)\n\n### B. Germline Testing Algorithm\n1. **Age-based approach**:\n   - **If <50 years**: Obtain comprehensive germline panel testing\n   - **If \u226550 years**: Consider genetic consultation based on personal/family history\n\n2. **Lynch Testing Pathway**:\n   - Based on pattern of MLH1, MSH2, MSH6, and PMS2 expression\n   - If MLH1/PMS2 loss: Perform MLH1 promoter hypermethylation testing\n   - Perform Lynch genetic testing if:\n     - Loss of MSH2, MSH6, MSH2/MSH6, or PMS2 expression\n     - Loss of MLH1 with negative MLH1 promoter hypermethylation\n     - MSI-H with BRAF unmutated and MLH1 unmethylated\n\n3. **Germline Panel Components**:\n   - Minimum genes: APC, AXIN2, BMPR1A, CHEK2, EPCAM, GALNT12, GREM1, MLH1, MLH3, MSH2, MSH3, MSH6, MUTYH, NTH1.1, PMS2, POLD1, POLE, PTEN, RNF43, SMAD4, STK11, TP53\n\n## III. STAGE-BASED MANAGEMENT PATHWAYS\n\n### A. Stage I Rectal Cancer\n1. **For partially endoscopically resected/biopsied lesions**:\n   - Surgical resection\n\n2. **For completely endoscopically resected polyps**:\n   - **If high-risk features present**: Surgical resection\n   - **If no high-risk features**:\n     - **Sessile polyps**: Shared decision-making (surgical resection vs. endoscopic surveillance)\n     - **Pedunculated polyps**: Endoscopic surveillance\n\n3. **High-Risk Features**:\n   - **Sessile polyps**: Poor differentiation, lymphovascular invasion, submucosal invasion >1mm, tumor involvement of cautery margin, tumor budding\n   - **Pedunculated polyps**: Poor differentiation, lymphovascular invasion, tumor within 1mm of resection margin\n\n### B. Stage II and III (pMMR) Rectal Cancer\n1. **Initial Requirements**:\n   - DPYD testing prior to fluoropyrimidine therapy\n\n2. **Treatment Algorithm**:\n   - **Decision point**: Candidate for omission of pre-operative radiation?\n     - **Eligibility criteria**: cT1-3N1+ or T3N0, no threatened CRM, tumor >5cm from anal verge, sphincter preservation not a concern, candidate for combination chemotherapy\n\n   - **If YES (omission pathway)**:\n     - Initial treatment: mFOLFOX6 or CAPOX (12 weeks)\n     - Response assessment with pelvic imaging\n     - If progression or tumor regression <20%: ChemoRT\n     - If no progression: Additional mFOLFOX6/CAPOX (12 weeks), then surgery\n\n   - **If NO (standard pathway)**:\n     - **Decision point**: Candidate for short-course RT?\n       - If YES: Short-course RT (without chemotherapy)\n       - If NO: ChemoRT (with infusional 5-fluorouracil or capecitabine)\n     - **Post-radiation decision**: Candidate for combination chemotherapy?\n       - If YES: Determine if aggressive approach indicated\n         - If aggressive approach indicated: FOLFRINOX (16-24 weeks), then surgery\n         - If not: mFOLFOX6 or CAPOX (16-24 weeks), then surgery\n       - If NO: Surgery followed by fluorouracil or capecitabine (16-24 weeks)\n\n3. **Complete Clinical Response Considerations**:\n   - **Assessment**: Pelvic MRI, CT, DRE, endoscopy (~8 weeks post-radiation)\n   - **If complete response**: Consider \"wait and watch\" approach with intensive surveillance\n\n4. **Aggressive Approach Criteria** (very fit patients with excellent performance status):\n   - T4, N2 disease\n   - Involved/threatened CRM on MRI\n   - Low-lying rectal cancer\n   - Extramural venous invasion\n\n### C. Stage IV Disease Management\n\n#### 1. Initial Evaluation and Branching\n- **Key decision point**: Disease resectability assessment\n  - **If resectable**: Follow Stage IV Potentially Resectable pathway\n  - **If unresectable**: Assess mismatch repair status\n    - **If dMMR/MSI-H**: Follow Stage IV Unresectable dMMR pathway\n    - **If pMMR/MSS**: Assess fitness for combination chemotherapy\n      - **If fit**: Follow appropriate Stage IV Unresectable pMMR pathway\n      - **If unfit**: Follow Stage IV Unresectable Unfit for Combination Chemotherapy pathway\n\n#### 2. Stage IV Potentially Resectable Pathway\n- **Initial requirements**: DPYD testing, multidisciplinary discussion\n- **If anatomically resectable**:\n  - mFOLFOX/FOLFIRI or CAPOX (up to 4 months) with short-course RT\n  - Metastasis and primary directed local therapy\n  - Complete remaining chemotherapy if needed (total 4-6 months)\n\n- **If not anatomically resectable but candidate for oxaliplatin**:\n  - **Decision point**: Aggressive approach indicated?\n    - **If YES** and bevacizumab candidate: FOLFRINOX \u00b1 bevacizumab (up to 4 months) with short-course RT\n    - **If YES** but not bevacizumab candidate: mFOLFOX/FOLFIRI \u00b1 bevacizumab (up to 4 months) with short-course RT\n    - **If NO**: FOLFIRI (up to 4 months) with short-course RT\n  - Reassess resectability every 2 months during treatment\n\n#### 3. Stage IV Unresectable dMMR Pathway\n- **First-line treatment**: Pembrolizumab immunotherapy\n- **If progression**: Assess fitness for combination chemotherapy\n  - Direct to appropriate pathway based on fitness assessment\n\n#### 4. Stage IV Unresectable pMMR - First Line\n- **Required testing**: DPYD testing, molecular status assessment (RAS, BRAF)\n- **Treatment by molecular status**:\n  - **RAS/BRAF wild-type**:\n    - If oxaliplatin candidate: mFOLFOX6/CAPOX + panitumumab\n    - If not oxaliplatin candidate: FOLFIRI + panitumumab\n  \n  - **RAS mutant, BRAF wild-type**:\n    - If oxaliplatin candidate:\n      - If bevacizumab candidate: mFOLFOX6/CAPOX + bevacizumab\n      - If not: mFOLFOX6/CAPOX alone\n    - If not oxaliplatin candidate:\n      - If bevacizumab candidate: FOLFIRI + bevacizumab\n      - If not: FOLFIRI alone\n\n#### 5. Stage IV Unresectable pMMR - Second Line\n- **Biomarker-directed options**:\n  - **BRAF V600E mutation**: Encorafenib + panitumumab\n  - **NTRK fusion**: Larotrectinib\n  - **HER2 overexpression + RAS/BRAF wild-type**: Trastuzumab + pertuzumab\n\n- **For RAS/BRAF wild-type patients**:\n  - **If prior anti-EGFR treatment**:\n    - If oxaliplatin candidate: mFOLFOX6/CAPOX \u00b1 bevacizumab\n    - If not: Assess KRAS G12C mutation\n      - If KRAS G12C mutation: Adagrasib + cetuximab\n      - If not: Trifluridine/tipiracil \u00b1 bevacizumab\n  - **If no prior anti-EGFR treatment**: FOLFIRI/irinotecan + panitumumab\n\n- **For other patients**:\n  - If prior irinotecan-based therapy: Switch to oxaliplatin-based therapy\n  - If prior oxaliplatin-based therapy: FOLFIRI \u00b1 bevacizumab\n\n#### 6. Stage IV Unresectable pMMR - Third Line\n- **Biomarker-directed options**:\n  - **HER2 overexpression**: Fam-trastuzumab deruxtecan\n\n- **RAS/BRAF wild-type pathway**:\n  - **If prior anti-EGFR treatment**:\n    - If prior trifluridine/tipiracil: Fruquintinib\n    - If not: Panitumumab\n  - **If no prior anti-EGFR treatment**: Adagrasib + cetuximab\n\n- **RAS mutant pathway**:\n  - **If KRAS G12C mutation**:\n    - If prior trifluridine/tipiracil: Fruquintinib\n    - If not: Trifluridine/tipiracil \u00b1 bevacizumab\n  - **If other RAS mutations**:\n    - If prior oxaliplatin-based therapy: FOLFIRI \u00b1 bevacizumab\n    - If prior irinotecan-based therapy: mFOLFOX6/CAPOX \u00b1 bevacizumab or trifluridine/tipiracil \u00b1 bevacizumab\n\n#### 7. Stage IV Unresectable pMMR - Fourth Line\n- **KRAS G12C mutation**: Adagrasib + cetuximab\n- **Other options if KRAS G12C negative**:\n  - Fruquintinib (if no prior failure)\n  - Trifluridine/tipiracil \u00b1 bevacizumab (if no prior failure)\n  - mFOLFOX6/CAPOX (if >12 months since last use, no significant neuropathy)\n  - FOLFIRI (if >12 months since last use)\n\n#### 8. Stage IV Unresectable, Unfit for Combination Chemotherapy\n- **First-line**: Fluorouracil or capecitabine monotherapy\n- **Second-line options**:\n  - **BRAF V600E**: Encorafenib + panitumumab\n  - **RAS mutant or BRAF non-V600E**: Irinotecan\n  - **KRAS G12C mutation**: Adagrasib + cetuximab\n  - **RAS/BRAF wild-type**:\n    - If HER2 overexpression: Trastuzumab + pertuzumab\n    - If not: Panitumumab\n\n## IV. CRITICAL CLINICAL CONSIDERATIONS\n\n### A. DPYD Testing\n- Required before fluoropyrimidine administration\n- For intermediate/poor metabolizers, consult pharmacist for dose adjustments\n- May proceed without results if delay would endanger patient with high disease burden\n\n### B. Treatment-Specific Contraindications\n\n#### 1. Oxaliplatin Contraindications\n- Prior adjuvant treatment within past 12 months\n- Preexisting neuropathy >grade 1\n- Patient preference to avoid neuropathy\n- Disease progression during or within 3 months of prior oxaliplatin therapy\n\n#### 2. Capecitabine Contraindications\n- Medication adherence concerns\n- Inability to self-report toxicity\n- Severe renal impairment (CrCl <30 ml/min)\n\n#### 3. Bevacizumab Contraindications\n- ECOG PS >2; ANC <1500/mm\u00b3\n- Non-healing wounds or recent fractures\n- Major surgery within prior 4 weeks\n- Bleeding disorders or coagulopathy\n- Recent GI perforation\n- Uncontrolled hypertension\n- Arterial thromboembolism\n- Symptomatic congestive heart failure\n- Significant arrhythmia\n- Active cocaine use\n\n#### 4. Anti-EGFR Agent Considerations\n- Cetuximab can be substituted with panitumumab in high-risk regions\n- No prior use of KRAS G12C inhibitor for adagrasib + cetuximab regimen\n\n### C. Response Assessment and Follow-up\n- **Complete response assessment**: Pelvic MRI, CT, DRE, endoscopy\n- **\"Wait and watch\" surveillance protocol**:\n  - Sigmoidoscopy with DRE and CEA: Every 3-4 months (years 1-2), then every 6 months (years 3-5)\n  - Rectal MRI: Every 6 months (years 1-2), then annually (years 3-5)\n  - CT chest/abdomen/pelvis: Annually for 5 years\n  - Colonoscopy: Years 1 and 4, then every 5 years\n\n### D. General Considerations\n- Clinical trials should always be considered throughout treatment\n- For assistance finding clinical trials: CancerClinicalTrialsNavigation@va.gov\n- Multidisciplinary discussion recommended for complex cases\n- \"Wait and watch\" approach for complete clinical responders should only be considered in centers with experienced multidisciplinary teams\n\nThis pathway represents a comprehensive approach to managing rectal cancer across all stages with attention to molecular profiling, staging, and personalized therapeutic selection based on individual patient factors and disease characteristics.",
    "thinking": "Based on the detailed analyses from each page of the document, I'll create a comprehensive summary of the rectal cancer clinical pathway. I'll organize it in a logical manner that follows the patient journey from diagnosis through various treatment options based on stage and molecular characteristics.\n\n# Comprehensive Summary of Rectal Cancer Clinical Pathway (VA 2025 Version)\n\n## I. INTRODUCTION AND INITIAL EVALUATION\n\n### A. Definition and Anatomic Considerations\n- Rectum is defined on rectal MRI as intestine that lies below a virtual line from the sacral promontory to the upper edge of the pubic symphysis and extending up to the anus\n\n### B. Initial Evaluation Process\n1. **Mode of diagnosis assessment**:\n   - Complete resection \u2192 Follow appropriate pathway based on pathological stage\n   - Biopsy/partially resected \u2192 Perform staging workup\n   \n2. **Staging Workup**:\n   - T and N staging: Rectal protocol MRI (preferred) or EUS (Endoscopic Ultrasound)\n   - M staging: CT of chest, abdomen, and pelvis (if MRI pelvis not performed)\n\n### C. Presumptive Service Connection for Veterans\n- Gastrointestinal cancer (including rectal cancer) may qualify for VA disability benefits if:\n  - Served on/after September 11, 2001 in: Afghanistan, Djibouti, Egypt, Jordan, Lebanon, Syria, Uzbekistan, or Yemen\n  - OR served on/after August 2, 1990 in: Southwest Asia theater of operations or Somalia\n\n## II. MOLECULAR TESTING FRAMEWORK\n\n### A. Somatic Testing by Stage\n1. **Stage I-III**:\n   - MMR status by IHC and/or microsatellite instability status by PCR\n   - If deficient (dMMR/MSI-H): Perform Lynch testing if germline testing not previously done\n   \n2. **Stage IV**:\n   - Comprehensive genomic profiling (CGP), MMR, and HER2 status by IHC\n\n### B. Germline Testing Pathway\n1. **If age <50 years**:\n   - Obtain germline testing panel\n   \n2. **If age \u226550 years**:\n   - Consider genetic consultation or referral based on personal/family history\n\n### C. Lynch Testing Algorithm\n- Based on pattern of MLH1, MSH2, MSH6, and PMS2 expression by IHC\n- If MLH1 or PMS2 expression is lost by IHC:\n  - Consider BRAF V600E IHC testing\n  - MLH1 promoter hypermethylation testing\n- Perform diagnostic Lynch genetic testing if:\n  - Loss of MSH2, MSH6, MSH2/MSH6, or PMS2 expression by IHC\n  - Loss of MLH1 expression by IHC with negative MLH1 promoter hypermethylation testing\n\n### D. Required Germline Panel Genes\n- APC, AXIN2, BMPR1A, CHEK2, EPCAM, GALNT12, GREM1, MLH1, MLH3, MSH2, MSH3, MSH6, MUTYH, NTH1.1, PMS2, POLD1, POLE, PTEN, RNF43, SMAD4, STK11, TP53\n\n## III. STAGE-SPECIFIC MANAGEMENT PATHWAYS\n\n### A. Stage I Rectal Cancer\n1. **If partially endoscopically resected/biopsied polyp/mass**:\n   - Surgical resection\n\n2. **If completely endoscopically resected polyp**:\n   - Evaluate for high risk features\n\n   - **High risk features present**:\n     - Surgical resection\n\n   - **No high risk features**:\n     - Sessile polyps: Shared decision-making between surgical resection or endoscopic surveillance\n     - Pedunculated polyps: Endoscopic surveillance\n\n3. **High Risk Features Definition**:\n   - **For sessile polyps**: Poor differentiation, lymphovascular invasion, submucosal invasion >1mm, tumor involvement of cautery margin, tumor budding\n   - **For pedunculated polyps**: Poor differentiation, lymphovascular invasion, tumor within 1mm of resection margin\n\n### B. Stage II and III (pMMR) Rectal Cancer\n1. **Initial Assessment**:\n   - DPYD testing required (consult pharmacist for intermediate/poor metabolizers)\n   - Determine if candidate for omission of pre-operative radiation\n\n2. **Candidates for omission of pre-operative radiation** (cT1-3N1+ or T3N0, no threatened CRM, tumor >5cm from anal verge, sphincter preservation not a concern, candidate for combination chemotherapy):\n   - Initial treatment: mFOLFOX6 or CAPOX (12 weeks)\n   - Response assessment (repeat pelvic imaging, consider flexible sigmoidoscopy)\n   - If progression or tumor regression <20%: ChemoRT\n   - If no progression: Additional 12 weeks of mFOLFOX6 or CAPOX, then surgery\n\n3. **Not candidates for omission of pre-operative radiation**:\n   - Assessment for short-course RT eligibility\n     - If eligible: Short-course RT (without chemotherapy)\n     - If not eligible: ChemoRT (with infusional 5-fluorouracil or capecitabine)\n\n4. **Post-radiation decision**:\n   - If candidate for combination chemotherapy:\n     - Assessment for aggressive approach (for very fit patients with T4, N2, involved/threatened CRM, low-lying rectal cancer, or extramural venous invasion)\n     - If aggressive approach indicated: FOLFRINOX (16-24 weeks), then surgery\n     - If aggressive approach not indicated: mFOLFOX6 or CAPOX (16-24 weeks), then surgery\n   - If not candidate for combination chemotherapy:\n     - Surgery followed by fluorouracil or capecitabine (16-24 weeks)\n\n5. **Complete response assessment** (for watchful waiting consideration):\n   - Pelvic MRI, CT of chest and abdomen\n   - Digital rectal examination (DRE)\n   - Direct endoscopic evaluation (preferably 8 weeks after radiation completion)\n   - Defined as no evidence of residual tumor on all evaluations\n\n6. **\"Wait and watch\" surveillance protocol** (for complete response):\n   - Sigmoidoscopy with DRE and CEA: Every 3-4 months (first 2 years), then every 6 months (years 3-5)\n   - Rectal MRI: Every 6 months (first 2 years), then annually (years 3-5)\n   - CT C/A/P: Annually for 5 years\n   - Colonoscopy: Years 1 and 4, then every 5 years\n\n### C. Stage IV Initial Evaluation\n1. **Initial Assessment**:\n   - Follow molecular testing pathway\n   - Multidisciplinary discussion\n\n2. **Resectability assessment**:\n   - If resectable \u2192 Stage IV Potentially Resectable pathway\n   - If unresectable \u2192 Mismatch repair status assessment\n\n3. **Mismatch repair status**:\n   - If dMMR (MSI-H) \u2192 Stage IV Unresectable dMMR pathway\n   - If pMMR (MSS) \u2192 Chemotherapy candidacy assessment\n\n4. **Chemotherapy candidacy**:\n   - If candidate \u2192 Follow Stage IV Unresectable pMMR pathway\n   - If not candidate \u2192 Follow Stage IV Unresectable Unfit for Combination Chemotherapy pathway\n\n### D. Stage IV Potentially Resectable\n1. **Initial Assessment**:\n   - DPYD testing\n   - Multidisciplinary discussion\n\n2. **If anatomically resectable**:\n   - mFOLFOX/FOLFIRI or CAPOX chemotherapy (up to 4 months) with short-course RT\n   - Metastasis and primary directed local therapy\n   - After 4-6 months total chemotherapy:\n     - If response satisfactory \u2192 Surveillance\n     - If additional therapy needed \u2192 Complete remaining chemotherapy\n\n3. **If not anatomically resectable**:\n   - Determine if candidate for oxaliplatin\n   \n   - **If candidate for oxaliplatin and aggressive approach indicated**:\n     - Evaluate candidacy for bevacizumab\n       - If candidate \u2192 FOLFRINOX with/without bevacizumab (up to 4 months) and short-course RT\n       - If not candidate \u2192 mFOLFOX/FOLFIRI with/without bevacizumab (up to 4 months) and short-course RT\n     - After therapy, reassess resectability:\n       - If resectable \u2192 Metastasis and primary directed local therapy\n       - If not resectable \u2192 Continue systemic chemotherapy and reassess resectability every 2 months\n   \n   - **If candidate for oxaliplatin but aggressive approach not indicated**:\n     - FOLFIRI (up to 4 months) and short-course RT\n\n### E. Stage IV Unresectable dMMR\n1. **First-line treatment**:\n   - Pembrolizumab (immunotherapy)\n\n2. **If progression occurs**:\n   - Assess fitness for combination chemotherapy:\n     - If fit \u2192 Follow Stage IV Unresectable pMMR First Line Fit for Chemotherapy pathway\n     - If unfit \u2192 Follow Stage IV Unresectable Unfit for Combination Chemotherapy pathway\n\n### F. Stage IV Unresectable pMMR, Fit for Combination Chemotherapy\n\n#### 1. First Line\n- **DPYD testing required** (consult pharmacist for intermediate/poor metabolizers)\n- **Treatment by molecular status**:\n\n  - **RAS wild-type, BRAF wild-type (RASwt, BRAFwt)**:\n    - If candidate for oxaliplatin: mFOLFOX6 or CAPOX and panitumumab\n    - If not candidate for oxaliplatin: FOLFIRI and panitumumab\n\n  - **RAS mutant, BRAF wild-type (RASmut, BRAFwt)**:\n    - If candidate for oxaliplatin:\n      - If candidate for bevacizumab: mFOLFOX6 or CAPOX and bevacizumab\n      - If not candidate for bevacizumab: mFOLFOX6 or CAPOX alone\n    - If not candidate for oxaliplatin:\n      - If candidate for bevacizumab: FOLFIRI and bevacizumab\n      - If not candidate for bevacizumab: FOLFIRI alone\n\n#### 2. Second Line\n- **Treatment options based on biomarker testing**:\n  - **BRAF V600E mutation**: Encorafenib and panitumumab\n  - **NTRK fusion**: Larotrectinib\n  - **HER2 overexpression** + RAS/BRAF wild type: Trastuzumab and pertuzumab\n\n- **For patients not fitting above categories**:\n  - If prior irinotecan-based therapy \u2192 Switch to oxaliplatin-based therapy\n  - If prior oxaliplatin-based therapy \u2192 FOLFIRI with/without bevacizumab\n\n- **For RAS wild type/BRAF wild type patients**:\n  - If prior anti-EGFR treatment:\n    - If candidate for oxaliplatin \u2192 mFOLFOX6 or CAPOX with/without bevacizumab\n    - If not candidate for oxaliplatin \u2192 Assess KRAS G12C mutation:\n      - If KRAS G12C mutation present \u2192 Adagrasib + cetuximab\n      - If KRAS G12C mutation absent \u2192 Trifluridine (TPI/TOL) with/without bevacizumab\n  - If no prior anti-EGFR treatment \u2192 FOLFIRI or irinotecan with panitumumab\n\n#### 3. Third Line\n- **Treatment options based on biomarker testing**:\n  - **HER2 overexpression**: Fam-trastuzumab deruxtecan\n\n- **RASw/BRAFwt pathway**:\n  - If prior anti-EGFR treatment:\n    - If prior trifluridine tipiracil \u2192 Fruquintinib\n    - If no prior trifluridine tipiracil \u2192 Panitumumab\n  - If no prior anti-EGFR treatment \u2192 Adagrasib + cetuximab\n\n- **RASmut/BRAFwt or RASmut/BRAFmut pathway**:\n  - If KRAS G12C mutation present:\n    - If prior trifluridine tipiracil \u2192 Fruquintinib\n    - If no prior trifluridine tipiracil \u2192 Assess bevacizumab candidacy:\n      - If candidate \u2192 Trifluridine tipiracil and bevacizumab\n      - If not candidate \u2192 Trifluridine tipiracil alone\n  - If KRAS G12C mutation absent:\n    - If prior oxaliplatin-based therapy \u2192 FOLFIRI with/without bevacizumab\n    - If prior irinotecan-based therapy \u2192 Assess oxaliplatin candidacy:\n      - If candidate \u2192 mFOLFOX6 or CAPOX with/without bevacizumab\n      - If not candidate \u2192 Trifluridine tipiracil with/without bevacizumab\n\n#### 4. Fourth Line\n- **Treatment by KRAS G12C mutation status**:\n  - **If KRAS G12C mutation present**: Adagrasib + cetuximab\n\n  - **If KRAS G12C mutation absent**, options include:\n    - Fruquintinib (if no prior failure)\n    - Trifluridine tipiracil and bevacizumab (if no prior failure to trifluridine tipiracil)\n    - mFOLFOX6 or CAPOX (if well tolerated when used previously with >12 months since last treatment and no grade 2+ neuropathy)\n    - FOLFIRI (if well tolerated when used previously with >12 months since last treatment)\n\n### G. Stage IV Unresectable, Unfit for Combination Chemotherapy\n1. **First-line treatment**:\n   - DPYD testing (if not already performed)\n   - Fluorouracil (infusional 5-fluorouracil monotherapy preferred; capecitabine may substitute if appropriate)\n\n2. **Second-line treatment** (if progression occurs):\n   - **BRAF V600E mutation**: Encorafenib and panitumumab\n   - **RASmut or BRAF non-V600E**: Irinotecan\n   - **KRAS G12C mutation**: Adagrasib + cetuximab\n   - **RASWt; BRAFwt**:\n     - If HER2 overexpression: Trastuzumab and pertuzumab\n     - If no HER2 overexpression: Panitumumab\n\n## IV. IMPORTANT CLINICAL CONSIDERATIONS\n\n### A. DPYD Testing\n- Required before fluoropyrimidine administration\n- For intermediate/poor metabolizers, consult with pharmacist\n- Withholding chemotherapy for 2-3 weeks awaiting results may endanger patients with high disease burden\n\n### B. Agent-Specific Contraindications\n\n#### 1. Oxaliplatin Contraindications\n- Adjuvant treatment in past 12 months\n- Preexisting neuropathy >1 grade\n- Patient preference to avoid neuropathy\n- For Stage IV: Disease progression within 12 months of adjuvant therapy or progressing on/within 3 months of completing oxaliplatin\n\n#### 2. Capecitabine Contraindications\n- Adherence issues\n- Inability to self-report toxicity\n- Severe renal impairment (CrCl <30 ml/min)\n\n#### 3. Bevacizumab Contraindications\n- ECOG PS >2; ANC <1500/mm\u00b3\n- Non-healing wound/fracture\n- Major surgery in prior 4 weeks\n- Bleeding disorder or coagulopathy\n- Recent GI perforation\n- Unstable cardiac condition\n- Uncontrolled HTN, arterial thromboembolism\n- Symptomatic CHF\n- Arrhythmia\n- Active cocaine use\n\n#### 4. Cetuximab Considerations\n- In high-risk regions, can be substituted by panitumumab\n- No prior use of KRAS G12C inhibitor\n\n### C. Aggressive Approach Criteria\nMay be considered in very fit patients with excellent performance status with high-risk disease defined as:\n- T4, N2\n- Involved or threatened CRM (MRI)\n- Low-lying rectal cancer\n- Extramural venous invasion\n\n### D. Clinical Trials\n- Clinical trials should always be considered throughout the pathway\n- For assistance finding a clinical trial, email CancerClinicalTrialsNavigation@va.gov"
  }
}